Clinical trial • Musculoskeletal
Zoledronic acid for Hip osteoarthritis
Clinical trial of Zoledronic acid for Hip osteoarthritis. Randomised, placebo (dose/schedule not specified)-controlled. 70 participants.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Hip osteoarthritis
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 28-04-2025
- First CTIS Authorization Date
- 15-05-2025
Trial design
Randomised, placebo (dose/schedule not specified)-controlled trial in Norway.
- Randomised
- Yes
- Comparator
- Placebo (dose/schedule not specified)
- Target Sample Size
- 70
Eligibility
Recruits 70 No vulnerable populations selected (isVulnerablePopulationSelected:false). Consent/assent handling not specified..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected:false). Consent/assent handling not specified.
Recruitment
- Planned Sample Size
- 70
- Recruitment Window Months
- 14
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 70
Norway
- Earliest CTIS Part Ii Submission Date
- 25-04-2025
- Latest Decision Or Authorization Date
- 15-05-2025
- Processing Time Days
- 20
- Number Of Sites
- 1
- Number Of Participants
- 70
Sites
- Site Name
- Martina Hansens Hospital AS
- Department Name
- Orthopedic
- Principal Investigator Name
- Morten Halkjær Iversen
- Principal Investigator Email
- Morten.Halkjaer.Iversen@mhh.no
- Contact Person Name
- Morten Halkjær Iversen
- Contact Person Email
- Morten.Halkjaer.Iversen@mhh.no
Sponsor
Primary sponsor
- Full Name
- Martina Hansens Hospital AS
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Norway
Investigational products
- Investigational Product Name
- Zoledronic Acid
- Active Substance
- Zoledronic acid
- Modality
- Small molecule
Related trials
Other published trials that may interest you.